20 results
6-K
EX-99.1
LSB
LakeShore Biopharma Co., Ltd
15 Aug 24
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
8:40am
Year 2025 strategy will focus on driving revenue growth, controlling expenses, and enhancing profit margins. We are implementing a comprehensive plan
6-K
EX-99.1
LSB
LakeShore Biopharma Co., Ltd
19 Apr 24
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
8:03am
on operational efficiencies, and leverage our refined inventory strategy and robust sales network to build sustainable shareholder value.”
Ms
POS AM
LSB
LakeShore Biopharma Co., Ltd
23 Jan 24
Prospectus update (post-effective amendment)
4:18pm
. Given the potential advantages of PIKA rabies vaccine over conventional products, YS Group intends to formulate a premium pricing strategy … a similar strategy as required by a comparable regulatory authority;
YS Group may propose to or be required to conduct post-market studies; and
YS
424B3
LSB
LakeShore Biopharma Co., Ltd
25 Sep 23
Prospectus supplement
6:12am
strategy and growth potential. The purchases also reflect their confidence in YS Biopharma's vision, mission, and commitment to delivering shareholder value
424B3
9s8dbvvnv04bck639j
25 Sep 23
Prospectus supplement
6:07am
6-K
EX-99.1
lhfy7
25 Aug 23
YS Biopharma Announces Purchase of Shares by Company Officers
8:00am
6-K
EX-99.1
pcvfjn4b9a8caja60ybm
16 Aug 23
YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024
8:00am
424B3
msfhnno3k52r9z t0x
15 Aug 23
Prospectus supplement
8:00am
POS AM
siiunb 5nh7pnw
8 Aug 23
Prospectus update (post-effective amendment)
4:06pm
20-F
uh7n7qvsx5abga3nc
26 Jul 23
Annual report (foreign)
4:02pm
424B3
vndtl6i
5 Jun 23
Prospectus supplement
4:03pm
F-1/A
7idjbtdj1 35wpqsi4
12 May 23
Registration statement (foreign) (amended)
4:05pm
F-1
i0cam8r6ajiwc
12 Apr 23
Registration statement (foreign)
8:49am
F-4
109xzm af
28 Dec 22
Registration of securities (foreign)
6:58am
DRS/A
w1v mm39io
7 Dec 22
Draft registration statement (amended)
12:00am
DRS/A
j4gluvxurdc7dsd71w1f
14 Nov 22
Draft registration statement (amended)
12:00am
DRS
vcs4qrmlik0l
3 Oct 22
Draft registration statement
12:00am
425
EX-99.2
ucg9d18 smyf4th
30 Sep 22
Business combination disclosure
9:25am
425
EX-99.1
suxmoojwglf6c
30 Sep 22
Business combination disclosure
9:25am
- Prev
- 1
- Next